Curia Small Molecule

Home | Curia Small Molecule | Development & Manufacturing | Steroids & Hormones

Steroids & Hormones

We are uniquely positioned to deliver variable batch size manufacturing for steroids and hormones, from early clinical through commercial. We are a center of excellence for these families, which means versatility and customization for our clients.

Our services are supported by our continuous improvement approach, ensuring non-productive time reduction, competitiveness through cost reduction and full support, offering excellent regulatory compliance and QA track record, ICH stability storage and the ability to dual qualify manufacturing lines to de-risk supply chain.

With required resources in Europe, CURIA removes the complexity with Steroids and Hormones manufacturing for clients to be focused on the patient. We are uniquely positioned to handle the most complicated challenges of manufacturing variable batch sizes for Steroids and Hormones (from Small to Medium Batch manufacturing), and along the full journey (from Clinical trial manufacturing through commercialization).

Curia has the ability to dual qualify manufacturing lines to de-risk supply chain, and with an excellent regulatory compliance and QA track-record.

Curia´s success in Steroids and Hormones field is based on 4 pillars:

  • Variety of manufacturing processes include more than 200 chemical steps that allow us to manufacture tons of different steroids every year, ranging from the simplest to the most complex chemistry.
  • Diversity of products and grades, which includes over 60 different steroids manufactured each year from OEB1 to OEB5, from five kilograms of that size to more than 500 kilograms. Also, micronized material and sterile grade are available.
  • Variety of our equipment: we have four chemical plants dedicated to steroids, plus a sterile line also dedicated to steroids. We also have a high potency suite with isolator technology, over 35 reactors from 100L to 10,000L, multifunctional filtration and drying (including freeze drying and lyophilization), and micronization capabilities. Curia is a center of excellence for particle size control (through controlled crystallization, mill, micronizer)
  • Our way-of-thinking:
    • Continuous Improvement Approach to innovate and respond to new requirements (as new salts, new compliance standards, new polymorphic forms)
    • Deliver to your timelines
    • Non-productive time reduction
    • Competitiveness through cost reduction

FAQ: Corticosteroids and Hormonal Therapies — History, Use & Future Outlook 

1. What are corticosteroids and hormonal therapies? 

Corticosteroids are synthetic drugs modeled after hormones produced by the adrenal cortex. They are primarily used for their antiinflammatory and immunosuppressive effects across conditions such as asthma, autoimmune diseases, and dermatological disorders. 

Hormonal therapies involve replacing or regulating natural hormones, including insulin, thyroid hormones, pituitary hormones, and growth hormones, essential for treating endocrine and metabolic diseases. 

2. How did corticosteroids originate historically? 

Corticosteroids emerged from early 20thcentury research into adrenal hormones. Synthetic versions were rapidly adopted for treating inflammation, autoimmune conditions, respiratory illnesses, allergies, and skin diseases due to their strong immunosuppressive effects.  

3. How have hormonal therapies historically evolved? 

Hormonal therapies grew out of advances in endocrinology, leading to treatments for diabetes, thyroid disorders, adrenal insufficiency, growth hormone deficiency, and reproductive hormone imbalance. Their development has closely followed increased understanding of glandular function and rising prevalence of endocrine disorders. 

4. What are the most common uses of corticosteroids today? 

Corticosteroids are widely used for: 

  • Respiratory diseases like asthma and COPD, where inhaled corticosteroids are firstline treatments.
  • Autoimmune diseases such as rheumatoid arthritis and lupus. 
  • Skin and allergic conditions, treated with topical, oral, or injectable forms. 
    Their broad availability across multiple dosage forms supports use in clinical and home settings.

    5. What medical conditions rely on hormonal or endocrine therapies? 

    Hormonal therapies treat: 

    • Diabetes, the primary global driver of endocrinology drug demand. 
    • Thyroid diseases, via thyroid hormone replacement.  
    • Growth hormone and pituitary disorders, using recombinant hormone therapies.
    •  Hormone replacement for adrenal and reproductive system disorders. 

      6. How big are the current markets for these therapies? 

      • The corticosteroids market is projected to grow from USD 5.89B in 2025 to USD 7.75B in 2030, driven by innovation in inhaled and targeted formulations and rising chronic disease prevalence. 
      • The endocrinology drugs market is far larger, expected to increase from USD 107.79B in 2025 to USD 144.86B in 2030, fueled by increases in diabetes and thyroid disorders. 

      7. Which regions are leading in corticosteroid and hormone therapy use? 

      North America leads due to advanced healthcare infrastructure and high adoption of chronic disease therapies. The AsiaPacific region is the fastestgrowing market thanks to rising disease prevalence and expanding healthcare access. 

      8. What innovations are shaping the future of corticosteroids? 

      Future corticosteroid development focuses on: 

      • Selective glucocorticoid receptor modulators (SGRMs) that reduce side effects. 
      • Digital inhalers and improved combination therapies for respiratory diseases. 
      • Targeted and safer formulations, especially for autoimmune and dermatology applications. 

      9. What future trends will impact hormonal and endocrine therapies? 

      Key trends include: 

      • Personalized medicine, with treatments tailored to genetics and metabolic profiles. 
      • Targeted therapies for thyroid, adrenal, and pituitary disorders.  
      • Wearable and devicebased treatments, including newly approved nonpharmacological endocrine therapies. 
      • Digital monitoring, enabling continuous management of hormonal conditions. 

      10. Why do these therapies remain crucial to society? 

      Despite being discovered several years ago, APIs such as hydrocortisone, betamethasone, and budesonide remain essential medicines today. Meeting modern demand for these molecules now depends on advanced manufacturing capabilities, particularly for highpotency and complex steroid chemistry. In parallel, novel steroid molecules with improved selectivity and safety profiles are expanding the future therapeutic landscape, increasing the need for advanced, flexible manufacturing capabilities. 

      Curia provides the specialized manufacturing, scale, and reliability needed to support both high‑volume legacy products and next‑generation steroid innovation